Medical Cannabis in Psychiatry

References
1 Behr HG. Von Hanf ist die Rede, Kultur und Politik einer Droge. Sphinx Verlag Basel. 1982
2 Fankhauser M. Rückblick. Cannabis in medicine - a medical-historical review. MMW Fortschr Med 2022; 164: 24-25 German PMID: 36195789
3 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use: A systematic review and Meta-analysis. JAMA 2015; 313: 2456-2473
4 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use. JAMA 2015; 314: 520
5 Krumholz HM, Nuti SV, Downing NS. et al. Mortality, hospitalizations, and expenditures for the medicare population. JAMA 2015; 314: 837
6 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use. JAMA 2015; 314: 2308
7 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use. JAMA 2016; 315: 1522
8 Abrams DI. The therapeutic effects of cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med 2018; 49: 7-11
9 Müller-Vahl KR. Cannabinoids in the treatment of selected mental illnesses: Practical approach and overview of the literature. Pharmcopsychiatry 2024; 57: 104-114
10 Dammann I, Rohleder C, Leweke FM. Cannabidiol and its potential evidence-based psychiatric benefits – a critical review. Pharmacopsychiatry 2024; 57: 115-132
11 Szejko N, Becher E, Heimann F. et al. Medical use of different cannabis strains: Results from a large prospective survey in Germany. Pharmcopsychiatry 2024; 57: 133-140
12 Das A, Hendershot C, Husain M. et al. Perceptions, experiences, and patterns of cannabis use in individuals with mood and anxiety disorders in the context of cannabis legalisation and medical cannabis program in Canada - a qualitative study. Pharmcopsychiatry 2024; 57: 141-151
13 Karst M. Overview: Chronic pain and cannabis-based medicines. Pharmcopsychiatry 2024; 57: 152-159
14 Broers B, Bianchi F. Cannabinoids for behavioral symptoms in dementia: An overview. Pharmcopsychiatry 2024; 57: 160-168